Trial Profile
Ponatinib Survey: Retrospective Evaluation of CML Patients in the National Compassionate Program According to the 648/96 Decree
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Expanded access
- 24 Oct 2022 Status changed from recruiting to discontinued.
- 04 Jan 2022 Planned End Date changed from 1 Dec 2018 to 1 Dec 2022.
- 04 Jan 2022 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2022.